Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

calcitonin salmon (Rx)Brand and Other Names:Fortical, Miacalcin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 200 IU/mL (Miacalcin)

nasal spray

  • 200 IU/actuation (Fortical, Miacalcin)
more...

Hypercalcemia

Initial dose: 4 IU/kg SC/IM q12hr  

May increase to 8 IU/kg SC/IM q12hr; may increase up to a maximum 8 IU/kg q6hr if unresponsive

Paget Disease

Initial dose: 100 IU SC/IM qDay

Maintenance: 50 IU/day or 50-100 IU every 1-3 days

Osteoporosis, Postmenopausal

Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 yr postmenopause

100 IU SC/IM every other day with calcium and vitamin D

Nasal Spray: 1 spray (200 IU) qDay, alternate nostrils daily

Dosing Considerations

Fracture reduction efficacy for postmenopausal osteoporosis has not been demonstrated

Reserve use for patients for whom alternative treatments are not suitable

Due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis (see Cautions)

Calcitonin-salmon nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women

Administration

Patients should receive adequate calcium (at least 1000 mg/day elemental calcium) and vitamin D (at least 400 IU/day)

Nasal spray

  • Store unopened nasal spray in the refrigerator
  • Before using the first dose, wait until the bottle has reached room temperature and prime the pump before it is used for the first time
  • To administer, the nozzle should be carefully placed into the nostril with the patient’s head in the upright position, then the pump should be firmly depressed toward the bottle
  • The pump should not be primed before each daily use

Safety and efficacy not established

Next

Interactions

Interaction Checker

calcitonin salmon and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Rhinitis (12%)

            1-10%

            Arthralgia (4%)

            Back pain (5%)

            Expistaxis (4%)

            Injection site reactions (10%)

            Nausea (10%)

            Headache (3%)

            Flushing of face or hands (2-5%)

            <1%

            Abdominal pain

            Possible allergic reactions

            Appetite decreased

            Edema of feet

            Eye pain

            Feverish sensation

            Nausea

            Nocturia

            Possible local irritative effects in the respiratory tract

            Salty taste

            Frequency Not Defined

            Tremors

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to calcitonin-salmon

            Cautions

            Serious hypersensitivity reactions, including fatal anaphylaxis, reported; consider skin testing prior to treatment

            Hypocalcemia associated with tetany has been reported; ensure adequate intake of calcium and vitamin D

            A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin-salmon-treated patients

            Circulating antibodies to calcitonin-salmon may develop, and may cause loss of response to treatment

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: excretion in milk unknown/not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Half-life

            43 min

            Onset

            Hypercalcemia: IM/SC: Initial effect takes 2 hour; max effect: 30 week

            Paget's disease: Few months to a year for neurologic symptoms to improve

            Other Information

            Duration: hypercalcemia: 6-8 hours

            Peak Plasma Time: IM/SC: 16-25 minutes, Intranasal: 31-39 minutes

            Bioavailability: Intranasal: 3%

            Metabolism: Kidney

            Excretion: Urine

            Mechanism of Action

            Inhibits osteoclastic bone resorption, decreases serum calcium, and increases renal excretion of phosphate, calcium, sodium magnesium and potassium by decreasing tubular reabsorption

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.